Novel lenalidomide-based combinations for treatment of multiple myeloma

Mauro Cives, Valeria Simone, Oronzo Brunetti, Vito Longo, Franco Silvestris

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.

Original languageEnglish
Pages (from-to)9-20
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume85
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Multiple Myeloma
Stem Cell Niche
Drug Approval
Immunotoxins
Proteasome Inhibitors
Neoplastic Stem Cells
Myelodysplastic Syndromes
Hematologic Neoplasms
Drug Combinations
Epigenomics
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Neoplasms
Anti-Inflammatory Agents
Monoclonal Antibodies
Clinical Trials
Safety
Incidence
Research
lenalidomide

Keywords

  • Bone resorption
  • Combination therapies
  • IMiDs
  • Lenalidomide
  • Multiple myeloma
  • New drugs

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Novel lenalidomide-based combinations for treatment of multiple myeloma. / Cives, Mauro; Simone, Valeria; Brunetti, Oronzo; Longo, Vito; Silvestris, Franco.

In: Critical Reviews in Oncology/Hematology, Vol. 85, No. 1, 01.2013, p. 9-20.

Research output: Contribution to journalArticle

Cives, Mauro ; Simone, Valeria ; Brunetti, Oronzo ; Longo, Vito ; Silvestris, Franco. / Novel lenalidomide-based combinations for treatment of multiple myeloma. In: Critical Reviews in Oncology/Hematology. 2013 ; Vol. 85, No. 1. pp. 9-20.
@article{4cff3a548969412b881f85d76b262f6b,
title = "Novel lenalidomide-based combinations for treatment of multiple myeloma",
abstract = "Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.",
keywords = "Bone resorption, Combination therapies, IMiDs, Lenalidomide, Multiple myeloma, New drugs",
author = "Mauro Cives and Valeria Simone and Oronzo Brunetti and Vito Longo and Franco Silvestris",
year = "2013",
month = "1",
doi = "10.1016/j.critrevonc.2012.06.008",
language = "English",
volume = "85",
pages = "9--20",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Novel lenalidomide-based combinations for treatment of multiple myeloma

AU - Cives, Mauro

AU - Simone, Valeria

AU - Brunetti, Oronzo

AU - Longo, Vito

AU - Silvestris, Franco

PY - 2013/1

Y1 - 2013/1

N2 - Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.

AB - Lenalidomide (LEN) is an immunomodulatory drug (IMiD) which exerts tumoricidal effects and has immunomodulatory, anti-inflammatory and anti-angiogenic properties that synergistically keep the tumor in remission. It is currently approved as second-line therapy for multiple myeloma (MM) and for 5q defective myelodysplastic syndrome, while ongoing studies are at present evaluating its role in both solid and hematologic malignancies. Based on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as well as with new compounds targeting the cancer stem cell niche. Preliminary data from clinical studies are encouraging and suggest a favorable safety profile, although the long-term tolerability of these combinatory regimens needs to be carefully evaluated since an increased incidence of new primary tumors associated with LEN treatment has recently been reported. Thus, from bench to bedside studies are required to design clinical trials for new drug combination approval.

KW - Bone resorption

KW - Combination therapies

KW - IMiDs

KW - Lenalidomide

KW - Multiple myeloma

KW - New drugs

UR - http://www.scopus.com/inward/record.url?scp=84870800589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870800589&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2012.06.008

DO - 10.1016/j.critrevonc.2012.06.008

M3 - Article

VL - 85

SP - 9

EP - 20

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -